Veeva Continues to Show a Combination of Growth and Resilience. Time to Buy the Stock?

As a leading software company catering to the healthcare sector, Veeva Systems (NYSE: VEEV) has provided solid growth while operating in a defensive industry. The stock has had a good year, up over 10%, but it has trailed the market over the past five years even as management takes the business in a new direction.Let's dive into the company's most recent results and see if now is the time to buy the stock.For its fiscal second quarter, ended in July, Veeva's revenue increased 15% to $676.2 million, which was well above the $666 million to $669 million it had expected. More importantly, subscription revenue jumped 19% to $561.3 million, above its $554 million forecast. Service revenue fell 4% to $114.9 million. Subscription revenue is high-margin and recurring, while service revenue is lower-margin and is less predictable. Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool